ADMA NASDAQ
ADMA Biologics, Inc.
1W: +0.0%
1M: +18.0%
3M: +25.9%
YTD: -38.1%
1Y: -27.4%
3Y: +251.4%
5Y: +906.4%
$11.17
+0.10 (+0.95%)
After Hours: $10.99 (-0.18, -1.61%)
Weekly Expected Move ±5.8%
$9
$10
$11
$11
$12
Credit Risk of going bust: lower than 57% of companies Debt: 7.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.10 (down 99.1%), ADMA Biologics, Inc. would be worth roughly what it owes.
Total debt $203.8M against a stock market value of $2.48B.
Distance to default 5.90 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $100.2M (short-term plus half of long-term), stock volatility 55.4%; Altman Z'' 7.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.10 (down 99.1%), ADMA Biologics, Inc. would be worth roughly what it owes.
Total debt $203.8M against a stock market value of $2.48B.
Distance to default 5.90 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $100.2M (short-term plus half of long-term), stock volatility 55.4%; Altman Z'' 7.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
📊 Key Metrics
TTM$512M
Revenue
+8.0% YoY
$169M
Net Income
-19.1% YoY
$116M
Free Cash Flow
+77.1% YoY
69.4%
Gross Margin
42.2%
Op. Margin
30.4%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE41.9%
ROA27.2%
ROIC35.5%
Valuation
P/E15.4
P/B6.2
EV/EBITDA8.6
Leverage
Debt/Equity0.50
Current Ratio6.97
Interest Cov.25.5x
Quality Scores
Piotroski F5/9
Altman Z6.66
Beneish M-2.21